Interleukin-1 beta single-nucleotide polymorphism's C allele is associated with elevated risk of gastric cancer in helicobacter pylori-infected Peruvians

Sebastian Gehmert
University of Texas M.D. Anderson Cancer Center

Billie Velapatiño
Universidad Peruana Cayetano Heredia

Phabiola Herrera
AB PRISMA

Jaqueline Balqui
AB PRISMA

Livia Santivañe
AB PRISMA

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation
Gehmert, Sebastian; Velapatiño, Billie; Herrera, Phabiola; Balqui, Jaqueline; Santivañe, Livia; Cok, Jamie; Vargas, Gloria; Combe, Juan; Passaro, Douglas J.; Wen, Sijin; Meyer, Frank; Berg, Douglas E.; and Gilman, Robert H., "Interleukin-1 beta single-nucleotide polymorphism's C allele is associated with elevated risk of gastric cancer in helicobacter pylori-infected Peruvians." American Journal of Tropical Medicine and Hygiene. 81, 5. 804-810. (2009).
https://digitalcommons.wustl.edu/open_access_pubs/1773

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Authors
Interleukin-1 Beta Single-Nucleotide Polymorphism’s C Allele is Associated with Elevated Risk of Gastric Cancer in Helicobacter pylori-Infected Peruvians


Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; Department of Surgery, Otto-von-Guericke University, Magdeburg, Germany; Laboratories of Investigación y Desarrollo, Facultad de Ciencias, Universidad Peruana Cayetano Heredia, Lima, Peru; Asociacion Benefica PRISMA, Department of Bioresearch, Lima, Peru; Department of Pathology, Hospital Nacional Cayetano Heredia, Lima, Peru; Department of Gastroenterology, National Major San Marcos University, Lima, Peru; Department of Gastroenterology, National Institute of Neoplastic Diseases, Lima, Peru; Division of Epidemiology and Biostatistics, University of Illinois School of Public Health, Chicago, Illinois; Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; Departments of Molecular Microbiology, Genetics, and Medicine, Washington University Medical School, St. Louis, Missouri; Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

Abstract. Particular alleles of the interleukin-1B (IL-1B) gene have been correlated with increased risk of atrophic gastritis and gastric cancer in the populations of East Asia and Europe. No such data exist from Peru, a developing country with a population genotypically different from others studied and with a high prevalence of Helicobacter pylori infection and gastric cancer. We conducted a case-control study comparing 334 hospitalized patients with atrophic gastritis or gastric cancer with 158 nonatrophic gastritis patients (controls). Conditional logistic regression analysis revealed that an increased risk of atrophic gastritis (odds ratio, 5.60) and gastric cancer (odds ratio, 2.36) was associated with the IL-1B-511 C allele. Our study is the first to establish this allele as a risk for these conditions. Given the high prevalence of H. pylori and recurrence rate after treatment, IL-1B-511 single-nucleotide polymorphism analysis may identify those individuals who would benefit most from robust H. pylori eradication efforts in Peru.

INTRODUCTION

Chronic infection by the gastric pathogen Helicobacter pylori is an early risk factor for gastric cancer, one of the most frequently lethal malignancies in Latin America, East Asia, and Eastern Europe. However, only a small fraction of the people infected with H. pylori develop this disease. The development of gastric cancer (GC) is considered to be multifactorial and probably conditioned by particular aspects of the human genotype and other factors, including nutrition, environment, and virulence of infecting H. pylori strains. It has recently been suggested that interaction between factors related to bacterial virulence and immune response of the hosts affects the outcome of H. pylori infection, which may be influenced by polymorphisms in both bacteria and host. In particular, polymorphisms in IL-1B and IL-1RN genes were found to be associated with increased risk for developing GC owing to an increased IL-1 beta level in the gastric mucosa in response to infection with H. pylori. However, reports from different parts of the world concerning association of gene polymorphisms with GC are not consistent, and the primarily Amerindian populations of Latin America differ significantly from most other well-studied human populations, not only in environment and lifestyle but also in H. pylori genotype. In Peru, gastric cancer is still the leading cause of death for both sexes; however, no data exist on whether particular IL-1B-511 and IL-1RN alleles are associated with development of chronic atrophic gastritis (ChAG) or GC in Peruvians. Most Peruvians are of low socioeconomic status, have had a chronic H. pylori infection since infancy, and are at high risk of GC. The purpose of this prospective study was to determine whether alleles of the cytokine IL-1B gene (site -511) and of the IL1 receptor antagonist (IL-1RN) associated with an increased risk of cancer in some populations are also associated with an increased risk for ChAG or GC in a Peruvian Amerindian population. We conducted a case-control study of 658 hospitalized patients diagnosed for gastric cancer, atrophic gastritis, or nonatrophic gastritis (controls).

MATERIALS AND METHODS

Patients. We conducted a hospital-based case-control study among 658 hospitalized patients recruited sequentially in two municipal hospitals in Lima, Peru, from January 2005 to December 2006. Patients with a history of cancer, a pregnancy, or a biopsy specimen that was inadequate for histopathologic study were excluded from further analysis (N = 324). Gastric biopsies without gastritis, though typical of modern industrialized societies, are a rarity in Peru because of high rates of chronic H. pylori infection (over 90% in adults from a low socioeconomic group). Thus, from the 334 subjects that were included in our study, we used 158 with nonatrophic gastritis (NAG) as our reference control group. For subjects with noncardia gastric cancer (intestinal type, n = 92; diffuse type, n = 41), controls were matched 1:1, and for cases with chronic atrophic gastritis (n = 43), controls were matched 2:1. Controls were frequency matched to subjects in age (±10 years), gender, and environmental risk factors (house material, water preparation, waste removal), because significant differences have been found between the groups.

All participants gave written consent for participation in this research study and were interviewed using a 130-item questionnaire that included personal characteristics, environmental risk factors, and personal and family medical history. Ethylenediamine-tetraacetic acid (EDTA) blood samples (4 mL) were obtained and stored at −20°C for later DNA extraction.
The protocol and consent were approved by the human study–ethics committees of The Johns Hopkins School of Public Health (Baltimore, MD) and AB PRISMA in Lima, Peru.

**Endoscopy.** All endoscopic examinations were routinely performed as described by Soto and others. Two gastric biopsies were obtained from the midantrum, two gastric biopsies from the midcorpus (lesser and greater curvature), and one gastric biopsy from the incisura angularis; gastric biopsies were also obtained from each visible lesion. One biopsy from each gastric site was subjected to histologic preparation, and one biopsy from midcorpus and midantrum was used for culture and polymerase chain reaction (PCR). All samples were coded for anonymity and accurate recordkeeping.

**Helicobacter pylori detection.** Helicobacter pylori infection was detected in gastric biopsies by culture, silver stain, and PCR for urease (ureB). Biopsies were considered positive if any of the three tests was positive and were considered negative only when all three tests were negative.

**Culture and staining.** One gastric corpus biopsy was homogenized, and the tissue suspension was spread on BHI blood agar and on Columbia CNA Agar plates (Becton, Dickinson and Co., Sparks, MD) and incubated under microaerobic conditions (O2, 5%; CO2, 10%; N2, 85%) at 37°C for 4 to 7 days, as previously described. Visible H. pylori colonies were identified by characteristic morphology, a positive urease test, and bacterial morphology after Gram staining (Sigma, St. Louis, MO). In addition, pathohistologic analysis was performed on biopsies from antrum, corpus, and incisura using Warthin-Starry silver stain, as described previously.

**Polymerase chain reaction.** One biopsy sample from the gastric antrum was used for DNA preparation using the QIAamp DNA Mini Kit (QIAGEN AG, Basel, Switzerland) according to the manufacturer’s instructions to detect H. pylori with PCR. Briefly, PCR was carried out in a 25 μL volume containing 10–20 ng of extracted DNA, 0.4 mM of each primer specific for a 460 bp segment of the ureB gene (UreB-sense 5′-CGT CCG GCA ATA GCT GCC ATA GT-3′ and UreB-antisense 5′-GTA GGT CCT GCT ACT GAA GCC GTA TTA-3′), standard PCR buffer, 0.25 mM of dNTP mix, 2.5 mM of MgCl2, 0.02 U of recombinant Taq DNA Polymerase (Invitrogen, Carlsbad, CA), and 0.1 μg/μL of bovine serum albumin, with the following cycling parameters: denaturation at 94°C for 5 minutes, 35 cycles of 94°C for 1 minute, annealing at 67°C for 1 minute, and elongation at 72°C for 1 minute; a final step of 5 minutes was used to complete DNA extensions at 72°C. The PCR products were electrophoresed in a 2% UltraPure (Invitrogen) agarose gel in 1X TAE buffer containing 0.5 mg/mL ethidium bromide (Fisher Scientific, Fair Lawn, NJ) and were visualized using Kodak digital science 1D software (Eastman Kodak Company, Rochester, NY) on a Dell workstation (Dell Computer Corporation, Round Rock, TX).

**Pathohistology.** One biopsy sample each from the antrum, corpus, and incisura were fixed in buffered formalin, embedded in paraffin, and stained with hematoxylin and eosin (Sigma). An experienced pathologist (JC) examined the coded slides without knowledge of the area of origin of the microsection, clinical data, or endoscopic characteristics. Grades of gastritis were classified according to the updated Sydney Classification System and are presented in Table 1.

Gastric carcinoma patients were subdivided according to Lauren’s classification as intestinal type and diffuse type. Each subject was diagnosed based on the most severe or pronounced finding from the pathohistologic study of the gastric biopsies.

**IL-1B and IL-1RN genotyping.** The DNA was extracted from gastric biopsy or blood specimens using the QIAamp DNA Mini Kit (QIAGEN AG) according to the manufacturer’s instructions. The PCRs were performed in a 25 μL reaction mixture filled to full volume with PCR water (Sigma).

For genotyping the position -511 cytokine IL-1B gene single-nucleotide polymorphism (SNP), a 305 bp fragment was amplified with 0.5 μM of each primer, 5′-TTG CAT TGA TCT GGT TCA TC -3′ (sense) and 5′-GGT TAG AAA TCT TCC CAC TT -3′ (antisense), using standard PCR protocol (see above) and optimized with 1.5 μM of MgCl2, and 0.06 U of recombinant Taq DNA Polymerase. Cycling parameters were denaturation at 95°C for 5 minutes followed by 35 cycles of 95°C for 30 seconds, 50°C for 30 seconds, 72°C for 30 seconds, and a final extension step for 5 minutes at 72°C. Thereafter, the PCR products were digested for 18 hours at 37°C with 10 U of AvaI enzyme (New England BioLabs, Beverly, MA) to distinguish allele T (AvaI-resistant; one fragment of 305 bp) versus allele C (AvaI-cut: fragments of 115 and 190 bp). The digested DNAs were electrophoresed on a 2% agarose gel, and data were recorded as detailed previously.

Either an intact fragment of 305 bp (alleles T) or two fragments of 190 bp and 115 bp (alleles C) were obtained using electrophoresis. Human genotypes could be homozygous C/C, T/T, or heterozygous C/T.

The diagnostic variable number of tandem repeat (VNTR) marker for IL-1RN alleles was genotyped by PCR as follows: 0.5 μM of each primer, 5′-CTG AGC AAC ACT CCT AT -3′ (sense) and 5′-TCT TGG TCT GCA GGT AA -3′ (antisense), were used with the cycling parameters used for IL-1B-511 genotyping, but with an annealing temperature of 55°C and 3 mM of MgCl2 in the buffer. The IL-1RN alleles were coded
as follows: Allele 1 (four repeats of the 86 bp region, 412 bp PCR product), allele 2 (two repeats, 240 bp), and allele 3 (three repeats, 326 bp). For statistical analysis, this polymorphism was treated as bi-allelic using categories of short-allele (S allele) with two repeats (allele 2) and long-allele (L allele) with three or more repeats (alleles 1 and 3).

Samples assayed by PCR product sequencing were also used as positive controls for internal validation of enzyme digestion. In addition, one-fifth of the analyzed samples were tested again using the same assay, with completely concordant results.

**Statistics.** Data were collected in a computerized database using double data entry to ensure accurate recording. Descriptive statistical analysis was calculated, including proportions, percentage, means, and standard deviations. Chi-square ($\chi^2$) and $t$ test were used to assess differences of frequency distributions among demographic characteristics of the study population. To calculate odds ratios (ORs) and 95% confidence intervals (CIs) for $IL-1B$-511 and $IL-1RN$ genotypes, a conditional logistic regression model adjusted for $H. pylori$ infection was applied. Stratification in an unconditional logistic regression model adjusted for IL-1RN VNTR states was associated with increased frequency of chronic atrophic gastritis (Table 4).

**RESULTS**

In total, 334 patients were successfully genotyped for the two polymorphisms in the $IL-1$ gene cluster. The demographic comparison of matched cases and controls is summarized in Table 2. Although 80.1% of patients were infected with $H. pylori$, the genotype frequencies in cases and controls did not deviate from the Hardy-Weinberg equilibrium (Table 3). Distribution of gastritis location and intestinal metaplasia (IM) were different between patients diagnosed for NAG and ChAG ($P < 0.001$). ChAG occurred more frequently in the antrum region and were more often associated with IM. No significant differences were revealed between both groups (NAG, ChAG) with regard to the chronicity of gastritis ($P = 0.17$) (Table 1).

**DISCUSSION**

Given a high rate of infection by virulent (CagA positive, VacA toxigenic) $H. pylori$ strains in the Amerindian Peruvian population, it has seemed likely that host genetic factors affect the risk of emergence and progression of premalignant lesions (chronic atrophic gastritis) in $H. pylori$-infected Peruvians, as in other populations. Here, we found that homozygosity for the C allele of the $IL-1B$-511 SNP was strongly associated with chronic atrophic gastritis (OR, 11.22) and GC (OR, 4.15), even

### Table 2

Demographic variables of matched cases and controls with different diagnoses

<table>
<thead>
<tr>
<th>Variable</th>
<th>Patients for ChAG risk analysis</th>
<th>Patients for GC risk analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NAG**†</td>
<td>ChAG*‡</td>
</tr>
<tr>
<td>Subjects (n)</td>
<td>86</td>
<td>43</td>
</tr>
<tr>
<td>Sex [male/female (%/%)]</td>
<td>52/34 (60.5/39.5)</td>
<td>26/17 (60.5/39.5)</td>
</tr>
<tr>
<td>Mean age ± SD (y)</td>
<td>64.0 (14.43)</td>
<td>67.2 (12.73)</td>
</tr>
<tr>
<td>$H. pylori$ infection (%)</td>
<td>88.4</td>
<td>76.7</td>
</tr>
<tr>
<td><strong>Hospital</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loyaza</td>
<td>63 (73.3)</td>
<td>28 (65.1)</td>
</tr>
<tr>
<td>INEN</td>
<td>23 (26.7)</td>
<td>15 (34.9)</td>
</tr>
<tr>
<td><strong>Location</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antrum</td>
<td>61 (70.9)</td>
<td>36 (83.7)</td>
</tr>
<tr>
<td>Corpus</td>
<td>25 (29.1)</td>
<td>7 (16.3)</td>
</tr>
</tbody>
</table>

*Controls are matched 2:1 (**1:1) to cases according age (± 10 years), sex, and environmental risk factors.
†Nonatrophic gastritis.
‡Chronic atrophic gastritis.
§Gastric cancer.
when heterozygosity was associated with these pathologies (OR, 4.79 and 2.17, respectively).

Our results agree with reports from Asia\textsuperscript{16–18} that also showed higher GC risk for subjects with the \textit{IL-1B}-511 T allele. In addition, Ikehara and others\textsuperscript{19} reported that the C allele was associated with progression of gastric cancer, and Matsukura and others\textsuperscript{20} found that the \textit{IL-1B}-511 C/C genotype was more prevalent in Japanese subjects with severe mucosal atrophy. In contrast, previous studies have reported that the \textit{IL-1B}-511 T allele and the \textit{IL-1RN}*2 allele are associated with ChAG or GC in Caucasians.\textsuperscript{21–23} The results of the \textit{IL-1B}-511 C allele association are very interesting, because four meta-analyses\textsuperscript{24–28} did not reveal concurrent evidence for the \textit{IL-1B}-511 T allele, and significant associations between \textit{IL-1B} SNP and GC were only found for Caucasians.

Differences in GC prevalence, \textit{H. pylori} infection, allele frequency, and ethnicity might account for the varied results found in Caucasian and Asian populations. This theory is supported by a study from China that showed a significant risk associated with \textit{IL-1B}-511 only for the population where \textit{H. pylori} infection was more prevalent.\textsuperscript{29} Rates of GC and \textit{H. pylori} infection in Peru are among the highest in the world.\textsuperscript{13,30} Moreover, the T allele frequency for control patients in our study population (T allele frequency = 0.8) is higher than that reported in Caucasians (T allele frequency ~0.3) and Asians (T allele frequency ~0.46). Our data agrees with previous data that have shown that variation of several factors might affect gene polymorphism associations.\textsuperscript{20,29}

Previous studies from Peru have shown that ChAG is found predominantly in the antrum region and is more severe than ChAG that is found in the body of the stomach.\textsuperscript{31–33} In the present study, we also found ChAG to occur more frequently in the antrum region, and only in this gastric site was an association between ChAG and the C allele statistically significant. However, conflicting results regarding mucosal \textit{IL-1B} alleles and the \textit{IL-1B}-511 SNP indicate that this association is dependent on the study population.\textsuperscript{34,35}

Our stratification analysis for the effects of the \textit{IL-1B} allele type on the subtype and location of GC reflected an increased risk for intestinal types of GC in the corpus (OR, 6.29) and for \textit{IL-1B}-511 C allele homozygosity. In line with these findings, Uemura and others\textsuperscript{3} reported that patients with \textit{H. pylori} infection, predominantly in the corpus, were at a significantly higher risk for intestinal gastric cancer. This finding emphasizes the importance of chronic atrophic gastritis and how its site of occurrence is affected by previous \textit{H. pylori} infection.

Taken together, the C allele has been associated with higher \textit{IL-1B} promoter activity and thus with \textit{IL-1B} synthesis.\textsuperscript{36} In

### Table 3

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Obs. no.</th>
<th>(exp.)</th>
<th>P value‡</th>
<th>Obs.</th>
<th>(exp.)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>\textit{IL-1B}-511</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C/C</td>
<td>3</td>
<td>(3.36)</td>
<td></td>
<td>7</td>
<td>(7.12)</td>
<td></td>
</tr>
<tr>
<td>C/T</td>
<td>28</td>
<td>(27.28)</td>
<td></td>
<td>21</td>
<td>(20.76)</td>
<td></td>
</tr>
<tr>
<td>T/T</td>
<td>55</td>
<td>(55.36)</td>
<td></td>
<td>15</td>
<td>(15.12)</td>
<td></td>
</tr>
<tr>
<td>\textit{IL-1RN}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*2/*2</td>
<td>16</td>
<td>(12.66)</td>
<td></td>
<td>8</td>
<td>(8.15)</td>
<td></td>
</tr>
<tr>
<td>*2/L</td>
<td>68</td>
<td>(40.67)</td>
<td></td>
<td>21</td>
<td>(20.70)</td>
<td></td>
</tr>
<tr>
<td>L/L</td>
<td>30</td>
<td>(32.66)</td>
<td></td>
<td>0.26</td>
<td>13</td>
<td>(13.15)</td>
</tr>
</tbody>
</table>

### Table 4

Conditional logistic regression analysis for the risk of chronic atrophic gastritis using nonatrophic gastritis subjects as control

<table>
<thead>
<tr>
<th>Genotype</th>
<th>NAG*</th>
<th>n (%)</th>
<th>ChAG†</th>
<th>n (%)</th>
<th>OR (95% CI)‡</th>
<th>P value‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>\textit{IL-1B}-511</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T/T</td>
<td>55 (64.0)</td>
<td>15 (34.9)</td>
<td>1.0 (Reference)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C/T</td>
<td>28 (32.6)</td>
<td>21 (48.8)</td>
<td>4.8 (1.65–13.83)</td>
<td>0.004</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C/C</td>
<td>3 (3.5)</td>
<td>7 (16.3)</td>
<td>11.2 (2.27–55.37)</td>
<td>0.003</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C carrier§</td>
<td>31 (36.0)</td>
<td>28 (65.1)</td>
<td>5.6 (2.02–15.51)</td>
<td>0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>\textit{IL-1RN}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L/L</td>
<td>30 (34.9)</td>
<td>13 (31.0)</td>
<td>1.0 (Reference)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*2/L</td>
<td>46 (53.5)</td>
<td>21 (50.0)</td>
<td>1.0 (0.44–2.34)</td>
<td>0.98</td>
<td></td>
<td></td>
</tr>
<tr>
<td>*2/*2</td>
<td>10 (11.6)</td>
<td>8 (19.0)</td>
<td>1.6 (0.48–5.39)</td>
<td>0.43</td>
<td></td>
<td></td>
</tr>
<tr>
<td>*2 carrier¶</td>
<td>16 (19.0)</td>
<td>6 (15.0)</td>
<td>1.1 (0.50–2.48)</td>
<td>0.79</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 5

Conditional logistic regression analysis for the risk of gastric cancer using nonatrophic gastritis subjects as control

<table>
<thead>
<tr>
<th>Genotype</th>
<th>NAG*</th>
<th>n (%)</th>
<th>GC†</th>
<th>n (%)</th>
<th>OR (95% CI)‡</th>
<th>P value‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>\textit{IL-1B}-511</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T/T</td>
<td>81 (60.9)</td>
<td>56 (42.1)</td>
<td>1.0 (Reference)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C/T</td>
<td>45 (33.8)</td>
<td>62 (46.6)</td>
<td>2.17 (1.23–3.84)</td>
<td>0.007</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C/C</td>
<td>7 (5.3)</td>
<td>15 (11.3)</td>
<td>4.15 (1.33–12.93)</td>
<td>0.014</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C carrier§</td>
<td>52 (39.1)</td>
<td>77 (57.9)</td>
<td>2.36 (1.36–4.11)</td>
<td>0.002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>\textit{IL-1RN}</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L/L</td>
<td>49 (36.8)</td>
<td>46 (34.6)</td>
<td>1.0 (Reference)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*2/L</td>
<td>68 (51.1)</td>
<td>71 (53.4)</td>
<td>1.03 (0.59–1.80)</td>
<td>0.91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>*2/*2</td>
<td>16 (12.0)</td>
<td>16 (12.0)</td>
<td>0.86 (0.34–2.14)</td>
<td>0.75</td>
<td></td>
<td></td>
</tr>
<tr>
<td>*2 carrier¶</td>
<td>84 (63.2)</td>
<td>87 (65.4)</td>
<td>0.99 (0.57–1.71)</td>
<td>0.99</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Controls and cases are matched 2:1 for age, sex, and environmental factors.
* Nonatrophic gastritis (controls).
† Chronic atrophic gastritis (cases).
‡ Conditional logistic regression model adjusted for \textit{H. pylori} infection.
§ Subjects with genotype C/T or C/C.
¶ Subjects with genotype *2/L or *2/*2.
terms of possible mechanisms for GC risk in Peruvians, the increased IL-1β mucosal levels might cause profound inhibition of gastric acid secretion, which makes the gastric corpus (where most parietal cells are located) more hospitable for *H. pylori* colonization after initial infection in the antrum.23,26 Local infection-induced inflammation in the corpus can exacerbate the elevated IL-1β levels and thereby increase gastric mucosal pH, which paves the way for a progression of premalignant mucosal changes.26 We propose that these bacterial-host mucosal pH, which paves the way for a progression of premalignant mucosal changes.26 We propose that these bacterial-host synergisms explain the strong 511 C allele SNP gastric cancer association reported here in our results. The fact that the IL-1B-511 C allele was not associated with an increased risk for the diffuse-subtype GC suggests a different pattern for the emergence of or at least a lower correlation to atrophy in gastric mucosa.

Further study is needed on the polymorphic IL-10 gene’s affect regarding the occurrence of premalignant lesions and GC in Peruvians. IL-10 serves as a counter balance in the inflammatory orchestra and antagonizes proinflammatory cytokines, especially IL-1β.41 The low IL-10 haplotype (IL-10-1082A, IL-10-819T, and IL-10-592A) has been reported to significantly increase the risk of noncardia gastric cancer, most likely by uncontrolled IL-1β activity causing a hyperinflammatory milieu.21 However, similar to IL-1B, contradictory data exist for the reported polymorphism in the IL-10 gene.22

Our IL-1RN polymorphism analyses did not show any significant association between *2 allele and gastric disease. This contrasts with several studies in Caucasian populations in which the risk of GC was associated with the presence of the IL-1RN*2 allele.23,24,42 The IL-1RN*2 allele has been reported with elevated IL-1α levels and thereby with higher IL-1β levels in *in-vitro* cell cultures.43 Helicobacter pylori virulence, other environmental factors, or human genetic factors may diminish the importance of these IL-1α variants as regulators of IL-1B receptor binding in the Peruvian population.

In conclusion, our study is the first to establish the C allele of the IL-1B-511 SNP as a risk factor for intestinal-type GC and its premalignant lesion, gastric atrophy, in a largely Amerindian population. These findings are consistent with the progression of histologic changes from chronic atrophic gastritis to intestinal types of GC and furthermore suggest differences in the processes leading to diffuse types of GC.

Our findings support the theory that inter-individual genetically determined differences of cytokine production affect outcomes in *H. pylori* infection and GC.45,46

In view of a high *H. pylori* prevalence and a high recurrence rate of treated infections in Peruvians,47 IL-1B-511 SNP might be an indicator of which patients would benefit from rigorous anti-*H. pylori* therapy and vigilant surveillance of their gastric mucosal changes by intermittent gastroscopies.

Table 6

<table>
<thead>
<tr>
<th>Location</th>
<th>Matched pairs</th>
<th>C/C vs T/T</th>
<th>C carrier* vs T/T</th>
<th>C carrier* vs T/T</th>
<th>P value†</th>
<th>OR (95% CI)†</th>
<th>P value†</th>
<th>OR (95% CI)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antrum</td>
<td>Control NAG‡</td>
<td>12 (13.3)§</td>
<td>21 (34.4)</td>
<td>23 (37.7)</td>
<td>38 (62.3)</td>
<td>12.72 (2.1–76.4)</td>
<td>0.005</td>
<td>4.00 (1.6–9.8)</td>
</tr>
<tr>
<td>Cases</td>
<td>ChAg¶</td>
<td>16 (16.7)</td>
<td>19 (52.8)</td>
<td>25 (69.4)</td>
<td>11 (30.6)</td>
<td>11.07 (0.2–4.8)</td>
<td>0.93</td>
<td>1.96 (1.0–3.7)</td>
</tr>
<tr>
<td>Cases</td>
<td>GC</td>
<td>13 (14.3)</td>
<td>36 (51.4)</td>
<td>39 (55.7)</td>
<td>31 (44.3)</td>
<td>11.03 (0.2–5.8)</td>
<td>0.97</td>
<td>1.85 (0.9–3.8)</td>
</tr>
<tr>
<td></td>
<td>IT-GC</td>
<td>12 (14.0)</td>
<td>25 (50.0)</td>
<td>27 (54.0)</td>
<td>23 (46.0)</td>
<td>11.30 (0.1–13.2)</td>
<td>0.82</td>
<td>2.56 (0.9–6.3)</td>
</tr>
<tr>
<td></td>
<td>DT-GC**</td>
<td>11 (15.0)</td>
<td>11 (55.0)</td>
<td>12 (60.0)</td>
<td>18 (40.0)</td>
<td>4.84 (0.1–300.6)</td>
<td>0.47</td>
<td>1.23 (0.1–12.6)</td>
</tr>
</tbody>
</table>

*Subjects with genotype C/C and C/T.
†Unconditional logistic regression model adjusted for *H. pylori* infection.
‡Nonatrophic gastritis.
§0 (%) single.
¶Chronic atrophic gastritis.
**Intestinal-type gastric cancer.

Received September 24, 2008. Accepted for publication July 14, 2009.

Acknowledgments: We thank Paula Maguña for technical support. We are grateful for the assistance of the gastroenterologists at the Hospital Arzobispo Loayza and the Instituto Especializado de Enfermedades Neoplasticas and for the generous cooperation of patients from those hospitals. We thank Kristi M. Speights from the Department of Scientific Publications at The University of Texas M. D. Anderson Cancer Center for critically reviewing and editing the manuscript. Our condolences to the family of Dr. Passaro, a brilliant epidemiologist, whose ideas initiated this study.

Financial support: This study was supported by an NIH grant (RO1 DK63041) to R. Gilman.

Authors’ addresses: Sebastian Gehmert, Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, 7435 Fannin Street, Houston, TX, 77030-4009, Tel: 1-713-834-6115, Fax: 1-713-834-6105, E-mail: s.gehmert@gmail.com. Billie Velapatiño, Universidad Peruana Cayetano Heredia, Department of Microbiology, Av. Honorio Delgado, No. 430, Urb. Ingeniería, San Martin de Porres, Lima, Peru, Tel: 011-511-3190025, Fax: 011-511-3284038, E-mail: bvelap@yahoo.com. Phabiola Herrera, AB PRISMA, Bioresearch, Carlos Gonzales No. 251, Urb. Maranga - San Miguel, Lima, Peru, Tel: 011-511-464 0221, Fax: 011-511-4640781. E-mail: phabiola@gmail.com. Jaqueline Balqui and Livia Santivañez, AB Prisma, Bioresearch, Carlos Gonzales No. 251, Urb. Maranga, San Miguel, Lima, Peru, Tel: 011-511-464 0221, Fax: 011-511-4640781, E-mail: jbalqui@yahoo.es and lisantivanez@yahoo.es. Jaime Cok, Department of Pathology, Hospital Nacional Cayetano Heredia, Av. Honorio Delgado 262, Urb. Ingeniería, San Martin de Porres, Lima, Peru, Tel: 011-511-482-0402, Fax: 011-511-482-0402 ext. 229, E-mail: jaimecok20@yahoo.com. Gloria Vargas, Department of Gastroenterology, National Major San Marcos University, Av. Germán Amezaga s/n, Lima, Peru, Tel: 011-619-7000, Fax: 011-619-7000, E-mail: gvrargas@inen.sld.pe. Juan Combe, Department of Gastroenterology, Hospital Arzobispo Loayza, Av. Alfonso Ugarte Nro. 848, Lima, Peru, Tel: 011-511-437310, Fax: 011-511-4373110, E-mail: jcombe@inen.sld.pe. Sijin Wen, The University of Texas M. D. Anderson Cancer Center, Department of Biostatistics, 1515 Holcombe Boulevard, Houston, TX 77030-4009, Tel: 1-713-794-4168, Fax: 1-713-563-4242, E-mail:
REFERENCES


